Spotlight on Bayer’s and Takeda’s Cell Therapy Strategy Part 2
In our part 1 Spotlight blast, Celltelligence discussed Bayer’s expanding position within the cell therapy space (see previous insight). Below, Celltelligence continues our analysis with an overview of Takeda’s approach while performing a head-to-head comparison of Bayer and Takeda in the cell therapy space.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.